|By PR Newswire||
|January 20, 2014 03:06 AM EST||
ALTER, Belgium, January 20, 2014 /PRNewswire/ --
- First ever pan-European perspective on optimal care identifies key challenges in this rare genetic disease
The first ever pan-European patient/carer perspective on optimal care of the rare genetic disorder phenylketonuria (PKU) has been published in the Orphanet Journal of Rare Diseases. This paper, supported by the European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria (E.S.PKU), underpins significant deficiencies and inequalities in medical and social care, and psychological support of those with PKU. It also makes the case for action to be taken to improve the detection and management of the condition on a number of fronts, including:
- Mandatory, universal screening for PKU in newborns
- Equal access to treatment and monitoring of the condition throughout Europe
- Agreeing new standards of best practice
- Establishing European Centres of Expertise
- Reimbursing all aspects of treatment
- Specific interventions for high-risk groups
- Increasing the number of available healthcare professionals where required and elevating the status of dietitians
- Access for patients to multi-disciplinary teams
- Training for carers to provide more comprehensive social support for people with PKU
The paper was been developed by consensus of a working group led by Tobias S Hagedorn, Executive Board member of the E.S.PKU and Chairman of the German PKU Society (Deutsche Interessengemeinschaft für Phenylketonurie und verwandte Stoffwechselstörungen DIG PKU), following a multi-national stakeholder workshop involving representatives from 15 different countries, and of the findings from a benchmark report previously developed by the E.S.PKU and presented at the European Parliament in February 2012.
Eric Lange, President of E.S.PKU said: "The publication of this consensus paper is a significant milestone in the collective effort to improve the treatment and management of PKU in Europe. It represents the most far-reaching attempt to date to capture the views of patients, professionals and advocates, providing a blueprint for universally supported guidance for clinical practice. Despite the availability of accurate screening techniques, dietary management protocols and effective treatments, PKU management remains under-resourced with unacceptable variations in care across a number of countries."
It is now hoped that European healthcare professionals will develop evidence-based guidelines for use in clinical practice based on the principles set out in the consensus paper. EU policy makers will also be briefed on the importance of taking a comprehensive, standardised approach to the management of the condition across the region.
The paper is an open access publication and freely available here: http://www.ojrd.com/content/8/1/191. Development of the paper was supported by an unrestricted grant from Merck Serono, a division of Merck KGaA, Darmstadt, Germany, with no influence on any content.
About Phenylketonuria (PKU)
PKU is a rare inherited disorder that affects around one in every 10,000 children born in Europe, with significant variations between countries. People with PKU have a deficient liver enzyme, making them unable to break down an amino acid found in food, called phenylalanine. Consequently, levels of this amino acid build up in the blood eventually causing damage to the brain and nervous system. PKU can be managed by life-long adherence to a special diet. In children, PKU, if left unmanaged, can cause irreversible brain damage resulting in decreased IQ, executive function deficits and mental retardation. The condition can also lead to slow reaction times, poor concentration, poor memory and emotional issues including depression, anxiety and irritability.
The European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria (E.S.PKU), established in 1987, is the umbrella organisation of around 30 national and regional associations from 28 countries. It represents the interests of people with PKU and those who care for them across Europe, supporting its members through EU advocacy work and engagement with the clinical community. The E.S.PKU itself is composed of a six-member Executive Board as well as a Scientific Advisory Committee, which keeps the board informed about the latest scientific developments on PKU. For more information, please visit: http://www.espku.org
For press enquiries, please contact:
Tobias S. Hagedorn
E-mail: [email protected]
Phone: +49-5221-122066 (It is best to contact Mr Hagedorn between 8 p.m. and 9 p.m. CET)